U 97167
Latest Information Update: 28 May 2003
Price :
$50 *
At a glance
- Originator Pharmacia Corporation
- Class Antibacterials; Oxazolidinones
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 16 Apr 2003 Pharmacia has been acquired by Pfizer
- 18 Jun 2001 No-Development-Reported for Bacterial infections in USA (Unknown route)
- 01 Feb 1996 New profile